GlassScriptPhysician profile
Tracey Candelora
NPI 1689754558
$4,077.01
in general payments reported to CMS, 2019-2025
27 companies · $694 in 2025
The $694 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $837 · 2022: $1,110 · 2023: $474 · 2024: $962 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $682.63 | 2021-2025 | Erleada, Akeega, Tecvayli |
| Daiichi Sankyo INC. | $664.54 | 2021-2025 | Enhertu, Injectafer |
| Jazz Pharmaceuticals INC. | $483.08 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.89 | 2024 | Opdivo |
| Genentech USA, INC. | $207.62 | 2021-2023 | Lunsumio |
| Exelixis INC. | $160.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $159.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.18 | 2021-2023 | Lynparza |
| Beigene USA, INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Trodelvy |
| Abbvie INC. | $124.99 | 2025 | |
| Glaxosmithkline, LLC. | $124.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.13 | 2021-2022 | |
| Caris Mpi, INC. | $111.62 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $103.71 | 2024 | Alunbrig |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $99.95 | 2021 | |
| Lilly USA, LLC | $90.16 | 2025 | |
| Celgene Corporation | $81.24 | 2021 | |
| Clovis Oncology, INC. | $41.68 | 2022 | |
| Amgen INC. | $36.17 | 2021 | |
| Tempus Ai, INC | $28.41 | 2024 | |
| Blueprint Medicines Corporation | $20.65 | 2025 | Ayvakit |
| G1 Therapeutics, INC. | $20.15 | 2022 | |
| Astellas Pharma US INC | $19.94 | 2024 | Vyloy |
| Deciphera Pharmaceuticals INC. | $18.68 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.60 | 2021 | |
| Seagen INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Candelora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.